New Delhi: A number of Indian companies such as Dr Reddy’s
Laboratories, Natco Pharma, Strides Pharma Science and Zydus Cadila are in talks with US-based
Gilead Sciences for licensing
remdesivir, a development that could bring down the cost of the potential therapy for Covid-19. “More companies are likely to sign licensing agreements for remdesivir. We will hear more announcements next week,” said an industry executive, who did not wish to be identified.
This week, Cipla, Jubilant Life Sciences,
Hetero and Mylan signed non-exclusive licensing agreements for the antiviral drug which received emergency use authorisation from the
US Food and Drug Administration after trial results showed that it halved the recovery time to five days for moderately affected patients.